Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

Costello, Michael; Shrestha, Bhushan; Eden, John; Sjöblom, Peter; Johnson, Neil

doi:10.1002/14651858.cd005552.pub2

Cited by 111 publications

(69 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The long-term effect of medical treatment on metabolic-vascular outcomes needs to be considered especially as some medical interventions could deteriorate the metabolic risk profile in PCOS. Treatment with oral contraceptives regulates menstrual cycles and sex hormone-binding globulin levels are increased, leading to decreased levels of free testosterone and decreased hirsutism scores (61). The possible metabolic side effects of oral contraceptives are debated.…”

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Glintborg

Andersen

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in premenopausal women. The syndrome is characterized by hyperandrogenism, irregular menses and polycystic ovaries when other etiologies are excluded. Obesity, insulin resistance and low vitamin D levels are present in more than 50% patients with PCOS, these factors along with hyperandrogenism could have adverse effects on long-term health. Hyperinflammation and impaired epithelial function were reported to a larger extent in women with PCOS and could particularly be associated with hyperandrogenism, obesity and insulin resistance. Available data from register-based and data linkage studies support that metabolic-vascular and thyroid diseases, asthma, migraine, depression and cancer are diagnosed more frequently in PCOS, whereas fracture risk is decreased. Drug prescriptions are significantly more common in PCOS than controls within all diagnose categories including antibiotics. The causal relationship between PCOS and autoimmune disease represents an interesting new area of research. PCOS is a lifelong condition and long-term morbidity could be worsened by obesity, sedentary way of life, Western-style diet and smoking, whereas lifestyle intervention including weight loss may partly or fully resolve the symptoms of PCOS and could improve the long-term prognosis. In this review, the possible implications of increased morbidity for the clinical and biochemical evaluation of patients with PCOS at diagnosis and follow-up is further discussed along with possible modifying effects of medical treatment.

show abstract

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

“…Treatment with metformin increases insulin sensitivity and improves ovulatory function in PCOS (61), whereas androgen levels and hirsutism scores are only mildly improved or unchanged (61,74). The first-line treatment modalities for pre-diabetes are lifestyle intervention and metformin treatment (75).…”

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Glintborg

Andersen

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Lifestyle interventional plans are specially recommended, particularly as they favor weight loss, reduce the risk for metabolic comorbidities and, in adolescents, may prevent progression to the classic phenotype of PCOS later in life. Notably, the use of metformin was not necessarily recommended in combination with lifestyle intervention for treatment of obesity (41,43).…”

Section: European Journal Of Endocrinologymentioning

confidence: 99%

European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: There is evidence for differences between endocrinologists and other specialists in their approach to diagnosis and management of the polycystic ovary syndrome (PCOS). Objective: A mailed survey consisting of a simple questionnaire aiming to understand current practice for diagnosis and management of the PCOS by specialists across Europe. Methods: The questionnaire consisted of 23 questions grouped to achieve information on i) the general characteristics of the respondents, ii) patients with PCOS seen by endocrinologists, iii) the main diagnostic criteria, iv) biochemical parameters used in the differential diagnosis of hyperandrogenism, v) long-term concerns, and, finally vi) treatment choices. A total of 357 questionnaires representing 13.3% of the members of European Society of Endocrinology (ESE) were available for final analysis; 93% of the respondents were endocrinologists Results: In relation to the diagnostic criteria, respondents were most likely to select menstrual irregularity as the most frequent criteria used for the diagnosis of PCOS although very high rates were achieved for the use of hirsutism and biochemical hyperandrogenism. It therefore appears that the NIH criteria were followed by the majority of respondents. The most frequent biochemical parameters in the differential diagnosis of hyperandrogenism were total testosterone or free androgen index. Obesity and type 2 diabetes were regarded as the principal long-term concerns for PCOS. The most common treatments for patients with PCOS were metformin (33%), lifestyle modification (25%), and oral contraceptives (22%). More direct treatments of infertility include clomiphene citrate alone or in combination with metformin, prescribed by 9 and 23%, respectively, whereas only 6% used other methods for induction of ovulation.

show abstract

“…Подобно многим патологическим состояниям, ожирение способствует развитию других заболева-ний, в том числе и нарушений репродуктивной фун-кции, и отягощает уже имеющиеся нарушения фер-тильности [9]. Несмотря на это, функциональное состояние половых желез при ожирении до сих пор изучено недостаточно.…”

Section: обсуждение результатовunclassified

Динаміка Антропометричних Показників У Жінок Фертильного Віку З Ожирінням При Різних Схемах Терапії

Ismailov¹,

Abduvakhabova²

2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

International journal of endocrinology Оригінальні дослідження /Original Researches/ ВведениеСогласно докладу комитета Всемирной органи-зации здравоохранения (ВОЗ) по ожирению, избы-точная масса тела и ожирение в настоящее время столь распространены, что влияют на здоровье населения больше, чем традиционные проблемы здравоохранения, в частности, голодание и ин-фекционные заболевания [1]. Распространенность ожирения увеличивается с возрастом, а после 50-60 лет масса тела обычно стабилизируется [2]. Более того, ожирение является фактором риска развития многих заболеваний и связано со значи-тельным числом состояний, приводящих к смер-ти [3]. К ним относятся сердечно-сосудистые заболевания, артериальная гипертензия (АГ), но-вообразования, нарушение свертываемости кро-ви и функции дыхательной системы, заболевания опорно-двигательного аппарата и кожи, а также репродуктивные расстройства как у мужчин, так и у женщин [4].По классификации ВОЗ различают эндокринное (алиментарное, гипотиреоидное, гипофизарное, железистое) и простое ожирение (избыточное, кон-ституциональное, локализованное, экзо-и эндоген-ное). В основе базисной терапии, назначаемой всем пациентам с ожирением, лежит изменение образа УДК 618.17-008.8:616-008.9 DOI: 10.22141/2224УДК 618.17-008.8:616-008.9 DOI: 10.22141/ -0721.13.2.2017 Исмаилов С.И., Абдувахабова М.Б.

show abstract

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

Cited by 111 publications

References 39 publications

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire

Динаміка Антропометричних Показників У Жінок Фертильного Віку З Ожирінням При Різних Схемах Терапії

Contact Info

Product

Resources

About